ClinicalTrials.gg
CompletedNCT03586973Updated Apr 18, 2023Results posted

A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Hepatocellular Carcinoma

A Phase 2 interventional study of Cabozantinib in Advanced Hepatocellular Carcinoma, sponsored by Takeda. Completed at 17 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2023-04-18.

Sponsored by Takeda · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
34
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing cabozantinib in Carcinoma, Hepatocellular — 7 open to participants now, 11 under way, 2 of them phase 3. cabozantinib · Carcinoma, Hepatocellular.

Enrollment
15th of 27
34 · median 35
Started
2018
with 3 others
Phase 2
17 of 27
5 open now
Registered
8th of 27
by date

Among the 27 studies testing cabozantinib in Carcinoma, Hepatocellular, this one is the 15th largest by enrollment, is one of 4 that started in 2018, is one of 17 in phase 2, and was the 8th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

7 of the 27 studies testing cabozantinib in Carcinoma, Hepatocellular are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About cabozantinib

cabozantinib: first FDA approval 2012 (COMETRIQ), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing cabozantinib in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of cabozantinib in Japanese participants with advanced hepatocellular carcinoma (HCC) who have received prior systemic anticancer therapy.

Read the detailed description

The drug being tested in this study is called Cabozantinib. Cabozantinib is being tested to treat advanced hepatocellular carcinoma in Japanese patients. This study will look at the efficacy and safety of Cabozantinib.

The study will enroll approximately 34 patients. Participants will be assigned to Cohort A (at least 17 participants) or Cohort B (approximately 15 participants) and will receive the following treatment. Participants who have received prior sorafenib will enroll to Cohort A and participants who have not received prior sorafenib will enroll to Cohort B.

  • Cabozantinib 60 mg

All participants will be asked to take one tablet of cabozantinib once daily in the fasted state (dose at least 2 hours after meal and no more food intake for 1 hour postdose) throughout the study.

This multi-center trial will be conducted in Japan. The overall time to participate in this study is approximately at most 3 years. Participants will make multiple visits to the clinic during the treatment and posttreatment period, including a follow-up assessment after last dose of study drug.

03

Conditions studied

  • Advanced Hepatocellular Carcinoma
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female Japanese participants 20 years of age or older on the day of consent.
  2. Histological or cytological diagnosis of HCC (results of a previous will be accepted).
  3. per (RECIST) 1.1 as determined by the investigator.
  4. Participants who have disease that is not amenable to a curative treatment approach (eg, transplant, surgery, radiofrequency ablation).
  5. Participants who have received 1 or 2 prior anticancer therapies for advanced HCC.

    • Cohort A: participants who have received prior sorafenib.
    • Cohort B: participants who have not received prior sorafenib. Note: Additional prior systemic therapies used as or local therapy are allowed.
  6. Radiographic progression following prior systemic anticancer therapy for advanced HCC.
  7. Recovery to =\<Grade 1 (CTCAE) Version 4.03 from toxicities related to any prior treatments, unless the Adverse Events (AEs) are clinically nonsignificant and/or stable on supportive therapy.
  8. (ECOG) performance status (PS) of 0 or 1, and of at least 3 months.
  9. Score of A.
  10. Adequate organ and marrow function at Screening (within 10 days before Week 1 Day 1):

    1. (ANC) >=1,200/mm\^3.
    2. >=60,000/mm\^3.
    3. >=8 g/dL.
    4. Serum creatinine =\<1.5 × (ULN) or calculated >=40 mL/min using the Cockroft-Gault equation.
    5. Urine protein-to-creatinine ratio (UPCR) =\<1 mg/mg Cr.
    6. Total =\<2 mg/dL.
    7. Serum albumin >=2.8 g/dL.
    8. (ALT) and aspartate aminotransferase (AST) =\<5.0 × ULN.
    9. (HbA1c) =\<8% (if HbA1c results are unavailable [eg, hemoglobin variant], a fasting serum glucose =\<160 mg/dL).
  11. Antiviral therapy per local standard of care if active virus (HBV) infection.
  12. Female participants who:

    1. Are (natural amenorrhea, not due to other medical reasons) for at least 1 year before the Screening visit, OR
    2. Are surgically sterile, OR
    3. If they are of , agree to practice 1 highly effective method of with a condom, which is an effective barrier method of contraception, at the same time, from the time of signing the through 4 months after the last dose of study drug, OR
    4. Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant, from the time of signing the informed consent through 4 months after the last dose of study drug. (Periodic abstinence [eg, calendar, ovulation, symptothermal, postovulation methods], condoms only, withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception.)

      Male participants, even if surgically sterilized (ie, status postvasectomy), who:

    5. Agree to practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug. If their partner are of childbearing potential, their female partner should use 1 highly effective method of birth control at the same time, OR
    6. Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant, from the time of signing the informed consent through 4 months after the last dose of study drug. (Periodic abstinence [eg, calendar, ovulation, symptothermal, postovulation methods for the female partner], condoms only, withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception.)
  13. Voluntary written consent must be given before performance of any study-related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the participant at any time without prejudice to future medical care.
  14. Participant is willing and able to adhere to the study visit schedule and other protocol requirements.

Exclusion criteria

Exclusion Criteria:

  1. Fibrolamellar carcinoma or mixed hepatocellular cholangiocarcinoma.
  2. Any type of anticancer agent within 14 days before the first day of study drug administration (Week 1 Day 1).
  3. Radiation therapy within 28 days (14 days for radiation for bone ) or radionuclide treatment (eg, I-131 or Y-90) within 42 days before Week 1 Day 1 (participant is excluded if there are any ongoing complications from prior radiation therapy).
  4. Prior Cabozantinib treatment.
  5. Treatment with any products (excluding anticancer products approved in Japan) within 28 days before Week 1 Day 1.
  6. Known or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 3 months before Week 1 Day 1. Eligible participants must be without treatment at Week 1 Day 1.
  7. Concomitant anticoagulation, with oral anticoagulants (eg, warfarin, direct thrombin and Factor Xa inhibitors) or inhibitors (eg, clopidogrel).

    Note: Low-dose aspirin for prophylactic use (per local applicable guidelines) and low-dose, low molecular weight heparins (LMWH) are permitted (LMWH has not been approved for the use for cardioprotection in Japan). Anticoagulation with therapeutic doses of LMWH is allowed in participants without radiographic evidence of brain metastasis, who are on a stable dose of LMWH for at least 12 weeks before Week 1 Day 1, and who have had no complications from a thromboembolic event or the anticoagulation regimen.

  8. Participants who have uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:

    1. Cardiovascular disorders including

      • Symptomatic congestive heart failure, unstable angina pectoris, or serious cardiac arrhythmias.
      • Uncontrolled hypertension defined as sustained blood pressure (BP) >150 mm Hg systolic, or >100 mm Hg diastolic despite optimal antihypertensive treatment.
      • Stroke (including [TIA]), myocardial infarction, or other ischemic event within 6 months before Week 1 Day 1.
      • Thromboembolic event within 3 months before Week 1 Day 1.
      • A left-ventricular =\<50%.
    2. Gastrointestinal (GI) disorders including those associated with a high risk of perforation or fistula formation:

      • Tumors invading the GI tract, active peptic ulcer disease, inflammatory bowel disease (eg, Crohn's disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, acute pancreatitis or acute obstruction of the pancreatic duct or common bile duct, or gastric outlet obstruction.
      • Abdominal fistula, GI perforation, bowel obstruction, intra-abdominal abscess within 6 months before Week 1 Day 1.

      Note: Complete healing of an intra-abdominal abscess must be confirmed prior to Week 1 Day 1.

    3. Major surgery within 2 months before Week 1 Day 1. Complete healing from major surgery must have occurred 1 month before Week 1 Day 1. Complete healing from minor surgery (eg, simple excision, tooth extraction) must have occurred at least 7 days before Week 1 Day 1. Participants with clinically relevant complications from prior surgery are not eligible.
    4. Cavitating pulmonary lesion(s) or endobronchial disease.
    5. Lesion invading a major blood vessel including, but not limited to: inferior vena cava, pulmonary artery, or aorta. Participants with invasion or thromboses of portal/hepatic vasculature attributed to underlying liver disease and/or liver tumor are eligible.
    6. Clinically significant bleeding risk including the following within 3 months before Week 1 Day 1: hematuria, hematemesis, hemoptysis of >0.5 teaspoon (>2.5 mL) of red blood, or other signs indicative of pulmonary hemorrhage, or history of other significant bleeding if not due to reversible external factors.
    7. Other clinically significant disorders such as:

      • Active infection requiring systemic treatment.
      • Known infection with , or known acquired immunodeficiency syndrome -related illness.
      • Active and/or C. Participants with active hepatitis virus infection controlled with antiviral therapy are eligible.
      • Serious non-healing wound/ulcer/bone fracture.
      • Malabsorption syndrome.
      • Uncompensated/symptomatic hypothyroidism.
      • Requirement for hemodialysis or peritoneal dialysis.
      • History of solid organ transplantation.
  9. Participants with untreated or incompletely treated varices with bleeding or high risk for bleeding. Participants treated with adequate endoscopic therapy (according to institutional standards) without any episodes of recurrent GI bleeding requiring transfusion or hospitalization for at least 6 months before Week 1 Day 1 are eligible.
  10. Moderate or severe ascites.
  11. interval calculated by the Fridericia formula (QTcF) >500 msec within 14 days before Week 1 Day 1.

    Note: If the QTcF is >500 msec in first (ECG), a total of 3 ECGs each separated by at least 3 minutes should be performed within 30 minutes. If the average of these 3 consecutive results for QTcF is =\<500 msec, the participant meets eligibility in this regard.

  12. Inability to swallow tablets.
  13. Previously identified allergy or to components of the study treatment formulations.
  14. Female participants who are lactating and breastfeeding or have a positive serum pregnancy test during the Screening period.

    Note: Female participants who are in the lactation period, even if they discontinue breastfeeding, will be excluded from the study.

  15. Previously diagnosed with another and have any evidence of residual disease within 2 years before Week 1 Day 1.

    Note: Participants with superficial skin cancers, or localized, low-grade tumors deemed cured and not treated with systemic therapy are not excluded.

  16. Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol.
  17. Known GI disease or GI procedure that could interfere with the oral absorption or tolerance of Cabozantinib.
  18. Use of strong cytochrome P450 (CYP) 3A inhibitors and inducers within 14 days before Week 1 Day 1.
  19. Admission or evidence of illicit drug use, drug abuse, or alcohol abuse.
Terms in these criteria, in plain language(34)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Cohort A: Cabozantinib 60 mg

    Participants who have received first/second line anticancer therapy with sorafenib were assigned to Cohort A and received cabozantinib 60 milligrams (mg), tablet, orally, once daily in the fasted state, up to approximately 2 years.

    Drug: Cabozantinib

  • Experimental
    Cohort B: Cabozantinib 60 mg

    Participants who did not receive first/second line anticancer therapy with sorafenib were assigned to Cohort B and received cabozantinib 60 mg, tablet orally, once daily in the fasted state, up to approximately 2 years.

    Drug: Cabozantinib

Interventions

06

What researchers measure

Primary outcomes

  1. 24-Week Progression-Free Survival Rate (PFSR)

    24-week PFSR=percentage of participants with progression-free survival (PFS) of at least 24 weeks at Week 25 Day 1 plus 7 days. PFS=time from first day of study drug administration to earlier of progressive disease (PD) or death due to any cause per Response Evaluation Criteria in Solid Tumors Version 1.1(RECIST 1.1). PD=at least a 20% increase in sum of target lesion diameters (SoD) with reference to smallest(nadir) SoD. In addition to relative increase of 20%, SoD must also demonstrate an absolute increase of at least 5 mm. For nontarget lesion time Point Response, unequivocal progression of nontarget lesions. Modest 'increase' in size of one or more nontarget lesions is usually not sufficient to quality for unequivocal progression status, it must not be representative of single lesion increase. Lesion in an anatomical location and not scanned at baseline is considered new lesion. Lesion qualifies as PD if finding is unequivocally not due to change in imaging technique or modality.

    Time frame: Week 25 Day 1 plus 7 days

Secondary outcomes

  1. Progression-Free Survival (PFS)

    PFS was defined as time from the first day of study drug administration to the earlier of PD per RECIST 1.1 as assessed by IRC or death due to any cause. Per RECIST 1.1, for target lesion time point response, PD was defined at least a 20% increase in the SoD of target lesions, taking as a reference the smallest (nadir) SoD since (and including) baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. For nontarget lesion time point response, unequivocal progression of nontarget lesions. A modest 'increase' in the size of one or more nontarget lesions is usually not sufficient to quality for unequivocal progression status. It must be representative of overall disease status change, not a single lesion increase. The lesion qualifies as a PD if the finding is unequivocally not due to a change in the imaging technique or modality.

    Time frame: Until disease progression, or death or end of study (Up to approximately 2.8 years)

  2. Objective Response Rate (ORR)

    ORR was defined as the percentage of participants whose best overall response was complete response (CR) or partial response (PR) per RECIST 1.1 as assessed by IRC, which was confirmed by a subsequent evaluation conducted \>= 28 days later. Per RECIST 1.1, for target lesion time point response, CR was defined disappearance of all target lesions. All pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \<10 mm. For nontarget lesion time point response, disappearance of all nontarget lesions. All lymph nodes must be nonpathological in size (\<10 mm short axis); PR was defined as at least a 30% decrease in SoD of target lesions, taking as a reference the baseline SoD.

    Time frame: Up to approximately 2 years

  3. Disease Control Rate (DCR)

    DCR=percentage of participants whose best overall response is CR,PR or SD, per RECIST 1.1, CR and PR require confirmation by subsequent evaluation conducted \>=28 days later, and SD have to be maintained for at least 8 weeks after first day of study drug administration. CR=disappearance of all target lesions. All pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \<10 mm. For nontarget lesion time point response, disappearance of all nontarget lesions. All lymph nodes must be nonpathological in size (\<10 mm short axis); PR=at least a 30% decrease in SoD of target lesions, taking as reference baseline SoD; SD=neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD; SoD must also demonstrate an absolute increase of at least 5 mm; PD=at least a 20% increase in SoD of target lesions, taking as a reference smallest (nadir) SoD.

    Time frame: Up to approximately 2 years

  4. Overall Survival (OS)

    OS was defined as time from the first day of study drug administration to death due to any cause. Participants without documentation of death were censored on the date they were last known to be alive.

    Time frame: Up to end of study (Up to approximately 2.8 years)

07

Results

Posted Apr 18, 2023

Participant flow

Participants took part in the study at 15 investigative sites in Japan from 06 August 2018 to 29 June 2021.

Participant flow — Overall Study
MilestoneCohort A: Cabozantinib 60 mgCohort B: Cabozantinib 60 mg
Started2014
Completed00
Not completed2014
Withdrew: Death158
Withdrew: Site terminated by sponsor36
Withdrew: Withdrawal by subject10
Withdrew: Lost to follow-up10

Outcome measures

Primary24-Week Progression-Free Survival Rate (PFSR)

24-week PFSR=percentage of participants with progression-free survival (PFS) of at least 24 weeks at Week 25 Day 1 plus 7 days. PFS=time from first day of study drug administration to earlier of progressive disease (PD) or death due to any cause per Response Evaluation Criteria in Solid Tumors Version 1.1(RECIST 1.1). PD=at least a 20% increase in sum of target lesion diameters (SoD) with reference to smallest(nadir) SoD. In addition to relative increase of 20%, SoD must also demonstrate an absolute increase of at least 5 mm. For nontarget lesion time Point Response, unequivocal progression of nontarget lesions. Modest 'increase' in size of one or more nontarget lesions is usually not sufficient to quality for unequivocal progression status, it must not be representative of single lesion increase. Lesion in an anatomical location and not scanned at baseline is considered new lesion. Lesion qualifies as PD if finding is unequivocally not due to change in imaging technique or modality.

Time frame:
Week 25 Day 1 plus 7 days
Reported as:
Number · percentage of participants
24-Week Progression-Free Survival Rate (PFSR)
percentage of participantsCohort A: Cabozantinib 60 mgCohort B: Cabozantinib 60 mg
24-Week Progression-Free Survival Rate (PFSR)59.8 (36.06 to 77.21)16.7 (4.02 to 36.82)
SecondaryProgression-Free Survival (PFS)

PFS was defined as time from the first day of study drug administration to the earlier of PD per RECIST 1.1 as assessed by IRC or death due to any cause. Per RECIST 1.1, for target lesion time point response, PD was defined at least a 20% increase in the SoD of target lesions, taking as a reference the smallest (nadir) SoD since (and including) baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. For nontarget lesion time point response, unequivocal progression of nontarget lesions. A modest 'increase' in the size of one or more nontarget lesions is usually not sufficient to quality for unequivocal progression status. It must be representative of overall disease status change, not a single lesion increase. The lesion qualifies as a PD if the finding is unequivocally not due to a change in the imaging technique or modality.

Time frame:
Until disease progression, or death or end of study (Up to approximately 2.8 years)
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsCohort A: Cabozantinib 60 mgCohort B: Cabozantinib 60 mg
Progression-Free Survival (PFS)7.4 (5.5 to 9.5)3.6 (1.8 to 5.6)
SecondaryObjective Response Rate (ORR)

ORR was defined as the percentage of participants whose best overall response was complete response (CR) or partial response (PR) per RECIST 1.1 as assessed by IRC, which was confirmed by a subsequent evaluation conducted \>= 28 days later. Per RECIST 1.1, for target lesion time point response, CR was defined disappearance of all target lesions. All pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \<10 mm. For nontarget lesion time point response, disappearance of all nontarget lesions. All lymph nodes must be nonpathological in size (\<10 mm short axis); PR was defined as at least a 30% decrease in SoD of target lesions, taking as a reference the baseline SoD.

Time frame:
Up to approximately 2 years
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsCohort A: Cabozantinib 60 mgCohort B: Cabozantinib 60 mg
Objective Response Rate (ORR)5.0 (0.127 to 24.873)0.0 (0.000 to 23.164)
SecondaryDisease Control Rate (DCR)

DCR=percentage of participants whose best overall response is CR,PR or SD, per RECIST 1.1, CR and PR require confirmation by subsequent evaluation conducted \>=28 days later, and SD have to be maintained for at least 8 weeks after first day of study drug administration. CR=disappearance of all target lesions. All pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \<10 mm. For nontarget lesion time point response, disappearance of all nontarget lesions. All lymph nodes must be nonpathological in size (\<10 mm short axis); PR=at least a 30% decrease in SoD of target lesions, taking as reference baseline SoD; SD=neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD; SoD must also demonstrate an absolute increase of at least 5 mm; PD=at least a 20% increase in SoD of target lesions, taking as a reference smallest (nadir) SoD.

Time frame:
Up to approximately 2 years
Reported as:
Number · percentage of participants
Disease Control Rate (DCR)
percentage of participantsCohort A: Cabozantinib 60 mgCohort B: Cabozantinib 60 mg
Disease Control Rate (DCR)85.0 (62.107 to 96.793)64.3 (35.138 to 87.240)
SecondaryOverall Survival (OS)

OS was defined as time from the first day of study drug administration to death due to any cause. Participants without documentation of death were censored on the date they were last known to be alive.

Time frame:
Up to end of study (Up to approximately 2.8 years)
Reported as:
Median · months
Overall Survival (OS)
monthsCohort A: Cabozantinib 60 mgCohort B: Cabozantinib 60 mg
Overall Survival (OS)19.3 (13.3 to 22.6)9.9 (3.6 to NA)

Adverse events

Collected over All-Cause Mortality: Up to end of study (Up to approximately 2.8 years); Serious and other adverse events: From first dose up to 30 days post last dose (Up to approximately 2 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A: Cabozantinib 60 mg15/20 (75%)7/20 (35%)20/20 (100%)
Cohort B: Cabozantinib 60 mg8/14 (57.1%)2/14 (14.3%)14/14 (100%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventCohort A: Cabozantinib 60 mgCohort B: Cabozantinib 60 mg
PyrexiaGeneral disorders0/201/14
CholangitisHepatobiliary disorders1/201/14
Hepatic encephalopathyNervous system disorders0/201/14
Gastrointestinal ulcerGastrointestinal disorders1/200/14
IleusGastrointestinal disorders1/200/14
BilomaHepatobiliary disorders1/200/14
CholelithiasisHepatobiliary disorders1/200/14
Liver abscessInfections and infestations1/200/14
Meningitis bacterialInfections and infestations1/200/14
Peritonitis bacterialInfections and infestations1/200/14
Most frequent other events
Showing 10 of 120
Most frequent other events
EventCohort A: Cabozantinib 60 mgCohort B: Cabozantinib 60 mg
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders16/2010/14
DiarrhoeaGastrointestinal disorders15/206/14
Platelet count decreasedInvestigations6/207/14
Decreased appetiteMetabolism and nutrition disorders8/207/14
HypertensionVascular disorders9/207/14
ConstipationGastrointestinal disorders1/206/14
Aspartate aminotransferase increasedInvestigations6/206/14
DysphoniaRespiratory, thoracic and mediastinal disorders8/200/14
Alanine aminotransferase increasedInvestigations5/205/14
HypothyroidismEndocrine disorders7/203/14

Baseline characteristics

Full Analysis Set (FAS) included participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Cohort A: Cabozantinib 60 mgCohort B: Cabozantinib 60 mgTotal
Mean72.2 ± 6.3271.6 ± 8.1372 ± 7.01
Sex: Female, Male
Sex: Female, Male(Participants)Cohort A: Cabozantinib 60 mgCohort B: Cabozantinib 60 mgTotal
Female303
Male171431
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort A: Cabozantinib 60 mgCohort B: Cabozantinib 60 mgTotal
Asian201434
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort A: Cabozantinib 60 mgCohort B: Cabozantinib 60 mgTotal
Not Hispanic or Latino201434
Region of Enrollment
Region of Enrollment(Participants)Cohort A: Cabozantinib 60 mgCohort B: Cabozantinib 60 mgTotal
Japan201434
Height
Height(centimeter (cm))Cohort A: Cabozantinib 60 mgCohort B: Cabozantinib 60 mgTotal
Mean162.2 ± 8.31165.4 ± 7.08163.5 ± 7.88
Weight
Weight(kilogram (kg))Cohort A: Cabozantinib 60 mgCohort B: Cabozantinib 60 mgTotal
Mean61.60 ± 9.12364.54 ± 11.35162.81 ± 10.042
Body Mass Index (BMI)
Body Mass Index (BMI)(kilogram per square meter (kg/m^2))Cohort A: Cabozantinib 60 mgCohort B: Cabozantinib 60 mgTotal
Mean23.34 ± 2.26223.46 ± 2.89423.39 ± 2.5

5 further baseline measures are reported on the registry.

08

Study locations

17 sites
  • Aichi Cancer Center Hospital
    Nagoya, Aichi, Japan
  • National Cancer Center Hospital East
    Kashiwa, Chiba, Japan
  • Iizuka Hospital
    Iizuka, Fukuoka, Japan
  • Kurume University Hospital
    Kurume, Fukuoka, Japan
  • Sapporo-Kosei General Hospital
    Sapporo, Hokkaido, Japan
  • Kanazawa University Hospital
    Kanazawa, Ishikawa, Japan
  • Kanagawa Cancer Center
    Yokohama, Kanagawa, Japan
  • Yokohama City University Medical Center
    Yokohama, Kanagawa, Japan
  • Kindai University Hospital
    Osakasayama, Osaka, Japan
  • National Cancer Center Hospital
    Chuo-ku, Tokyo, Japan
  • Kyorin University Hospital
    Mitaka, Tokyo, Japan
  • Japanese Red Cross Musashino Hospital
    Musashino, Tokyo, Japan
  • Chiba University Hospital
    Chiba, Japan
  • Hiroshima University Hospital
    Hiroshima, Japan
  • Okayama University Hospital
    Okayama, Japan
  • Osaka City University Hospital
    Osaka, Japan
  • Osaka International Cancer Institute
    Osaka, Japan
09

References and documents

Publications

  • Kudo M, Tsuchiya K, Kato N, Hagihara A, Numata K, Aikata H, Inaba Y, Kondo S, Motomura K, Furuse J, Ikeda M, Morimoto M, Achira M, Kuroda S, Kimura A. Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study. J Gastroenterol. 2021 Feb;56(2):181-190. doi: 10.1007/s00535-020-01753-0. Epub 2021 Jan 3. PubMed 33392749 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2018 to primary completion in Jul 2019, 11 months.

Results were first posted in Apr 2023, 3 years 9 months after primary completion.

Of 80 industry-sponsored phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 50. This study's 11 months is below that.

Counting every sponsor, half of 429 studies reached it within 43 months; a quarter within 30 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2018
First posted
Jul 16, 2018
StartActual
Aug 6, 2018
Primary completionActual
Jul 17, 2019
CompletionActual
Jun 29, 2021
Results first posted
Apr 18, 2023
Last update
Apr 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03586973
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Jul 16, 2018
Start date
Aug 6, 2018
Primary completion
Jul 17, 2019
Completion
Jun 29, 2021
Results posted
Apr 18, 2023
Last update
Apr 18, 2023

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabozantinib

Start the discussion